By Noémie Bisserbe
PARIS--French bank Société Générale SA said Thursday that fourth-quarter net profit soared, bouncing back from a hefty fine imposed by European regulators for colluding with other lenders to manipulate key benchmark interest rates.
Fourth-Quarter Revenue Down 12%; Up 5% in Constant Dollars1 Fourth-Quarter Operating Margin 7.3%, Up from (0.6)% in 2013 Fourth-Quarter Adjusted1 Operating Margin 9.3%, Up from 8.2% in 2013
Full-Year Revenue Down 11%; Relatively Unchanged in Constant Dollars Full-Year Operating Margin 4.5%, Up from 4.3% in 2013 Full-Year Adjusted Operating Margin 8.3%, Up from 7.9% in 2013 NEW YORK , Feb.
Manchester United (NYSE: MANU; the “Company” and the “Group”) – one of
the most popular and successful sports teams in the world - today
announced financial results for the 2015 fiscal second quarter and six
months ended 31 December 2014.
International (NASDAQ: CSGS) , a global provider of interactive
transaction-driven solutions and services, today announced that one of
Chile’s leading telecom service providers has awarded CSG a multi-year
managed services contract for the operation and management of its
wholesale and roaming systems.
Absolute Software Reports Fiscal 2015 Second Quarter Results Canada NewsWire
Strong corporate and education sales drive a 15% increase in total Commercial Sales Contracts and a 44% growth in cash from operating activities VANCOUVER , Feb.
Spectrum Pharmaceuticals (NasdaqGS: SPPI) , a biotechnology
company with fully integrated commercial and drug development operations
with a primary focus in Hematology and Oncology, today announced results
of a clinical study of Propylene Glycol (PG)-Free, Captisol-enabled
Melphalan (CE Melphalan) Conditioning for Autologous Hematopoietic Stem
Cell Transplantation (AHCT) in Patients with Multiple Myeloma (MM).
Spectrum filed a New Drug Application (NDA) for approval of CE-Melphalan
in December 2014 and expects a decision from the Food and Drug
Administration (FDA) by late 2015.
International Flavors & Fragrances Inc. (NYSE:IFF), a leading global
creator of flavors and fragrances for consumer products, today reported
financial results for the fourth quarter and full year ended January 2,
Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing
drugs to treat cancer by the targeted killing of cancer stem cells,
today announced that VS-5584 has received orphan drug designation from
the U.S. Food and Drug Administration for use in the treatment of
Incyte Corporation (Nasdaq: INCY) today reported 2014 fourth-quarter and
year-end financial results, including revenue from Jakafi ®
(ruxolitinib). The Company provided 2015 financial guidance while
outlining its progress in recruiting multiple pivotal and
proof-of-concept trials, including those investigating its portfolio of
JAK inhibitors in a variety of cancer types, its IDO1 inhibitor in
combination with other immuno-oncology agents and a series of studies
investigating several other innovative targeted therapies in mono- and
Rentech Nitrogen Partners, L.P. (NYSE: RNF) announced today that its
Board of Directors has declared a cash distribution of $0.30 per common
unit for the fourth quarter of 2014, payable on February 27, 2015 to
holders of record as of February 23, 2015.
Resonant Inc. (NASDAQ: RESN) a late-stage development company that is
creating innovative filter designs for radio frequency, or RF,
front-ends for the mobile device industry, today announced it will
release financial results for the fourth quarter and year ended December
31, 2014, after market close on Thursday, February 26, followed by an
investor conference call at 2:00 p.m. PST/5:00 p.m. EST.
Independent. Insightful. Trusted. Morningstar provides stock market analysis; equity, mutual fund, and ETF research, ratings, and picks; portfolio tools; and option, hedge fund, IRA, 401k, and 529 plan research. Our reliable data and analysis can help both experienced enthusiasts and newcomers.